Stereoselective pharmacokinetics of RS-8359, a selective and reversible MAO-A inhibitor, by species-dependent drug-metabolizing enzymes

Chirality

Volumn 17, Issue 3, 2005, Pages 135-141

  Takasaki, Wataru ^a   Yamamura, Mayumi ^a   Nozaki, Akiko ^a   Nitanai, Takashi ^a   Sasahara, Kunihiro ^a   Itoh, Kunio ^b   Tanaka, Yorihisa ^b  

^a DAIICHI SANKYO CO   (Japan)

^b TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Aldehyde oxidase; Chiral HPLC; Enantioselectivity; Metabolism; Pharmacokinetics; RS 8359; Species difference; Urine

Indexed keywords

4 (4 CYANOANILINO) 6,7 DIHYDRO 7 HYDROXY 5H CYCLOPENTA[D]PYRIMIDINE; ALDEHYDE OXIDASE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CYTOCHROME P450; DRUG METABOLITE; DRUG METABOLIZING ENZYME; KETONE DERIVATIVE; MONOAMINE OXIDASE A INHIBITOR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONFORMATION; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; ENANTIOMER; HUMAN; HUMAN EXPERIMENT; INTESTINE ABSORPTION; MALE; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RACEMIC MIXTURE; RAT; SPECIES DIFFERENCE; STEREOCHEMISTRY;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; DOGS; HUMANS; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED STRAINS; MONOAMINE OXIDASE INHIBITORS; NITRILES; PYRIMIDINES; RATS; RATS, WISTAR; SPECIES SPECIFICITY; STEREOISOMERISM;

EID: 14844300091     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/chir.20124     Document Type: Article

References (25)

1. Iwata N, Yokoyama T. RS-2232 and 8359, a new reversible and specific inhibitors of A form of MAO. Pharmacol Toxicol 1987;60 (Suppl 1):25 p.
2. Yokoyama T, Karube T, Iwata N. Comparative studies of the effects of RS-8359 and safrazine on monoamine oxidase in vitro and in vivo in mouse brain. J Pharm Pharmacol 1989;41:32-36.
3. Kumagae Y, Matsui Y, Iwata N. Participation of type A monoamine oxidase in the activated deamination of brain monoamines shortly after reperfusion in rats. Jpn J Pharmacol 1990;54:407-413.
4. Kumagae Y, Matsui Y, Iwata N. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359. Jpn J Pharmacol 1991;55:121-128.
5. Miura H, Naoi M, Nakahara D, Ohta T, Nagatsu T. Changes in monoamine levels in mouse brain elicited by forced-swimming stress, and the protective effect of a new monoamine oxidase inhibitor, RS-8359. J Neural Transm Gen Sect 1993;94:175-187.
6. Kozuka M, Kobayashi K, Iwata N. Effects of RS-8359 on reduced local cerebral glucose utilization in the rat subjected to transient forebrain ischemia. Jpn J Pharmacol 1994;64:257-264.
7. Iwata N, Tonohiro T, Kozuka M, Kumagae Y, Takasaki W, Tanaka Y. A novel selective and reversible MAO-A inhibitor, RS-8359: its pharmacological properties and metabolism. Int Acad Biomed Drug Res 1996;11:285-286.
8. Puchler K, Schaffler K, Plenker A. The comparative effects of single and multiple doses of RS-8359, moclobemide and placebo on psychomotor function in healthy subjects. Int Clin Psychopharmacol 1997;12(Suppl 5):S17-S23.
9. Plenker A, Puchler K, Volz HP. The effects of RS-8359 on cardiovascular function in healthy subjects and depressed patients. Int Clin Psychopharm 1997;12:S25-S29.
10. Iwabuchi H, Takasaki W, Kuwano H, Kobayashi T, Tanaka Y. Structural determination of rat and dog urinary metabolites of a new antidepressant RS-8359. Xenobiot Metab Dispos (Yakubutsu Dotai) 1998;13:351-361.
11. Drayer DE. Pharmacodynamic and pharmacokinetic differences between drug enantiomers in human: an overview. Clin Pharmacol Ther 1986;40:125-133.
12. Caldwell J, Winter SM. The pharmacological and toxicological significance of the stereochemistry of drug disposition. Xenobiotica 1988;18:59-70.
13. Testa B, Mayer JM. Stereo selective drug metabolism and its significance in drug research. Prog Drug Res 1988;32:249-303.
14. Jamali F, Mehvar R, Pasutto FM. Enantioselective aspects of drug action and disposition: therapeutic pitfalls. J Pharm Sci 1989;78:695-715.
15. Asami N, Shigeta A, Tanaka Y. Disposition of CS-670, a novel nonsteroidal anti-inflammatory drug, and its metabolism in healthy human volunteers. Chirality 1996;8:207-213.
16. Izumi T, Hoshiyama K, Enomoto S, Sasahara K, Sugiyama Y. Pharmacokinetics of troglitazone, an antidiabetic: prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data. J Pharmacol Exp Ther 1997;280:1392-1440.
17. Tucker GT, Lennard MS. Enantiomer specific pharmacokinetics. Pharmacol Ther 1999;45:309-329.
18. Katsuki H, Hamada C, Arimori K, Nakano M. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. Eur J Clin Pharmacol 2001;57:709-715.
19. Takasaki W, Yamamura M, Shigehara E, Suzuki Y, Tonohiro T, Hara T, Tanaka Y. Stereoselective pharmacokinetics of RS-8359, a selective and reversible inhibitor of A-type monoamine oxidase, in rats, mice, dogs, and monkeys. Biol Pharm Bull 1999;22:498-503.
20. Puchler K, Sasahara K, Plenker A, Nitanai T, Witte PU. The pharmacokinetic profile of RS-8359. Int Clin Psychopharmacol 1997;12(Suppl 5): S11-S16.
21. Shindo H, Kawai K, Maesa T, Igarashi I, Tajima M, Sugawara S. Absorption, distribution, excretion and metabolism of a new cephamycin antibiotic, CS-1170, in various animal species. Chemotherapy 1978;26:99-114.
22. Tamai I, Ling HY, Timbui SM, Nishikido J, Tsuji A. Stereospecific absorption and degradation of cephalexin. J Pharm Pharmacol 1988; 40:320-324.
23. Takanaga H, Tamai I, Inaba S, Sai Y, Higashida H, Yamamoto H, Tsuji A. cDNA cloning and functional characterization of rat intestinal monocarboxylate transporter. Biochem Biophys Res Commun 1995; 217:370-377.
24. Ogihara T, Tamai I, Takanaga H, Sai Y, Tsuji A. Stereoselective and carrier-mediated transport of monocarboxylic acids across Caco-2 cells. Pharm Res 1996;13:1828-1832.
25. Ogihara T, Tamai I, Tsuji A. In situ and in vitro evidence for stereoselective and carrier-mediated transport of monocarboxylic acids across intestinal epithelial tissue. Biol Pharm Bull 2000;23: 855-859.